Press Releases 2008

  • 11/12/2008
    IntelGenx Reports Results for the Nine Months Ended September 30, 2008
  • 10/10/2008
    IntelGenx Corp. set to file NDA for antidepressant
  • 09/05/2008
    IntelGenx Welcomes New Chief Financial Officer, Paul Simmons
  • 07/30/2008
    IntelGenx Corp. and Cary Pharmaceuticals Inc. Announce Successful End-of-Phase II Meeting with FDA for Development of their Antidepressant CPI-300
  • 06/03/2008
    IntelGenx Technologies Corp. Engages Auctus Capital Partners Inc. To Perform Investor Relations Activities
  • 05/22/2008
    IntelGenx Technologies Corp. Approved for trading on the TSX-Venture Exchange
  • 04/14/2008
    IntelGenx Corp. Forms Strategic Alliance with Dava Pharmaceuticals to Develop Cardiovascular Product Addressing a U.S. Market of $1.0 Billion
  • 04/07/2008
    IntelGenx Corp. and Cary Pharmaceuticals Confirm Agreement to Develop a Novel Antidepressant
  • 03/28/2008
    IntelGenx Technologies Corp. announces closing of private placement
  • 01/07/2008
    IntelGenx Corp. Forms Strategic Agreement with Azur Pharma to Develop Prenatal Vitamin Supplements Addressing a U.S. Market of $250 million